Cannabidiol Therapy, EHP-101, Put on Fast Track by FDA.
EHP-101, an oral therapy based on cannabidiol (CBD), has been placed on fast track development by the U.S. Food and Drug Administration (FDA) as a potential treatment of systemic scleroderma. Scleroderma News, 03/06/2020. (Also see Endocannabinoid System)
This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.